Chemical structure: aminoglycosideGentamicn-Glutamine solution is used for selection of transformed cells that contain the aacA.aphD gene, and is recommended for use in cell culture applications at 10 mL/L.
Description
Chemical structure: aminoglycosideGentamicn-Glutamine solution is used for selection of transformed cells that contain the aacA.aphD gene, and is recommended for use in cell culture applications at 10 mL/L.
Component：Formulated with 200 mM L-glutamine, 10,000 units/ml penicillin, and 10 mg/ml streptomycin in 0.9% sodium chloride.Used to reduce or eliminate bacterial contamination in cell, especially primary cell, cultures. Recommended for use in cell culture applications at 10 ml/L.
Description
Component：Formulated with 200 mM L-glutamine, 10,000 units/ml penicillin, and 10 mg/ml streptomycin in 0.9% sodium chloride.Used to reduce or eliminate bacterial contamination in cell, especially primary cell, cultures. Recommended for use in cell culture applications at 10 ml/L.
Component：This solution is formulated to contain 200 mM L-glutamine, 10,000 units of Penicillin and 10 mg/mL of streptomycin, solubilized in a proprietary buffer.This antibiotic solution is used to reduce or eliminate bacterial contamination in primary cell cultures. It is recommended for us at 10 mL/L.
Description
Component：This solution is formulated to contain 200 mM L-glutamine, 10,000 units of Penicillin and 10 mg/mL of streptomycin, solubilized in a proprietary buffer.This antibiotic solution is used to reduce or eliminate bacterial contamination in primary cell cultures. It is recommended for us at 10 mL/L.
The GS System™(offered by and a registered trademark of Celltech Biologicals, Inc.) utilizes specific vectors for cell culture transfection. Specialty Media offers media and reagents for use with this system. Our GS System products are made using the highest quality reagents and our high purity Ultra Pure H2O.Storage and Stability: Store at -20°C upto 1 year.
Description
The GS System™(offered by and a registered trademark of Celltech Biologicals, Inc.) utilizes specific vectors for cell culture transfection. Specialty Media offers media and reagents for use with this system. Our GS System products are made using the highest quality reagents and our high purity Ultra Pure H2O.Storage and Stability: Store at -20°C upto 1 year.
相关属性
品牌
Jinpan
法律信息
GS System is a trademark of Lonza Group Ltd.Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but
V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 µM) in HEK-293 cells[1].
IC50 & Target
ASCT2[1]
体外研究 (In Vitro)
V-9302 inhibits ASCT2-mediated glutamine uptake in human cells in a concentration-dependent fashion and exhibits a 100-fold improvement in potency over gamma-L-glutamyl-p-nitroanilide[1]. Pharmacological blockade of ASCT2 with V-9302 results in attenuated cancer cell growth and proliferation, increases cell death, and increases oxidative stress[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
V-9302 (75 mg/kg; i.p.; daily fo 21 days) prevents tumor growth in both HCT-116 and HT29 xenograft models[1]. The combination of CB-839 and V-9302 (30 mg/kg; i.p.; SNU398 and MHCC97H cells were grown as tumor xenografts in BALB/c nude mice; for 20 or 15 d, respectively) elicits a strong growth inhibition in both SNU398 and MHCC97H xenograft models, while single-drug treatment showed modest anti-tumor effects[2]. V-9302 (50 mg/kg ; i.p.; daily for 5 days) displays markedly reduced tumor growth[3].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
[1]. Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202.
[2]. Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5.
[3]. Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100.
V-9302 hydrochloride is a competitive antagonist of transmembrane glutamine flux. V-9302 hydrochloride selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 hydrochloride inhibits ASCT2-mediated glutamine uptake (IC50=9.6 µM) in HEK-293 cells[1].
IC50 & Target
ASCT2[1]
体外研究 (In Vitro)
V-9302 hydrochloride inhibits ASCT2-mediated glutamine uptake in human cells in a concentration-dependent fashion and exhibits a 100-fold improvement in potency over gamma-L-glutamyl-p-nitroanilide[1]. Pharmacological blockade of ASCT2 with V-9302 hydrochloride results in attenuated cancer cell growth and proliferation, increases cell death, and increases oxidative stress[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
V-9302 hydrochloride (75 mg/kg; i.p.; daily fo 21 days) prevents tumor growth in both HCT-116 and HT29 xenograft models[1]. The combination of CB-839 and V-9302 (30 mg/kg; i.p.; SNU398 and MHCC97H cells were grown as tumor xenografts in BALB/c nude mice; for 20 or 15 d, respectively) elicits a strong growth inhibition in both SNU398 and MHCC97H xenograft models, while single-drug treatment showed modest anti-tumor effects[2]. V-9302 (50 mg/kg ; i.p.; daily for 5 days) displays markedly reduced tumor growth[3].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
[1]. Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202.
[2]. Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5.
[3]. Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100.
